Literature DB >> 24584631

Carbon-carbon bond cleavage in activation of the prodrug nabumetone.

Fatbardha Varfaj1, Siti N A Zulkifli, Hyoung-Goo Park, Victoria L Challinor, James J De Voss, Paul R Ortiz de Montellano.   

Abstract

Carbon-carbon bond cleavage reactions are catalyzed by, among others, lanosterol 14-demethylase (CYP51), cholesterol side-chain cleavage enzyme (CYP11), sterol 17β-lyase (CYP17), and aromatase (CYP19). Because of the high substrate specificities of these enzymes and the complex nature of their substrates, these reactions have been difficult to characterize. A CYP1A2-catalyzed carbon-carbon bond cleavage reaction is required for conversion of the prodrug nabumetone to its active form, 6-methoxy-2-naphthylacetic acid (6-MNA). Despite worldwide use of nabumetone as an anti-inflammatory agent, the mechanism of its carbon-carbon bond cleavage reaction remains obscure. With the help of authentic synthetic standards, we report here that the reaction involves 3-hydroxylation, carbon-carbon cleavage to the aldehyde, and oxidation of the aldehyde to the acid, all catalyzed by CYP1A2 or, less effectively, by other P450 enzymes. The data indicate that the carbon-carbon bond cleavage is mediated by the ferric peroxo anion rather than the ferryl species in the P450 catalytic cycle. CYP1A2 also catalyzes O-demethylation and alcohol to ketone transformations of nabumetone and its analogs.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24584631      PMCID: PMC3989788          DOI: 10.1124/dmd.114.056903

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  25 in total

1.  Rate-determining steps in phenacetin oxidations by human cytochrome P450 1A2 and selected mutants.

Authors:  C H Yun; G P Miller; F P Guengerich
Journal:  Biochemistry       Date:  2000-09-19       Impact factor: 3.162

2.  Simultaneous determination of hemes a, b, and c from pyridine hemochrome spectra.

Authors:  E A Berry; B L Trumpower
Journal:  Anal Biochem       Date:  1987-02-15       Impact factor: 3.365

3.  In vitro evaluation of the anti-estrogenic activity of hydroxyl substituted diphenylnaphthyl alkene ligands for the estrogen receptor.

Authors:  Jonathan M Schmidt; Gilles B Tremblay; Michael A Plastina; Fupeng Ma; Sanjivanjit Bhal neé Basra; Miklos Feher; Robert Dunn-Dufault; Peter R Redden
Journal:  Bioorg Med Chem       Date:  2005-03-01       Impact factor: 3.641

4.  4-(6-Methoxy-2-naphthyl)butan-2-one and related analogues, a novel structural class of antiinflammatory compounds.

Authors:  A C Goudie; L M Gaster; A W Lake; C J Rose; P C Freeman; B O Hughes; D Miller
Journal:  J Med Chem       Date:  1978-12       Impact factor: 7.446

5.  Metabolism of nabumetone (BRL 14777) by various species including man.

Authors:  R E Haddock; D J Jeffery; J A Lloyd; A R Thawley
Journal:  Xenobiotica       Date:  1984-04       Impact factor: 1.908

6.  Analytical power of LLE-HPLC-PDA-MS/MS in drug metabolism studies: identification of new nabumetone metabolites.

Authors:  Milan Nobilis; Jiří Mikušek; Barbora Szotáková; Robert Jirásko; Michal Holčapek; Chamseddin Chamseddin; Thomas Jira; Radim Kučera; Jiří Kuneš; Milan Pour
Journal:  J Pharm Biomed Anal       Date:  2013-03-19       Impact factor: 3.935

7.  Preclinical overview of nabumetone. Pharmacology, bioavailability, metabolism, and toxicology.

Authors:  F R Mangan; J D Flack; D Jackson
Journal:  Am J Med       Date:  1987-10-30       Impact factor: 4.965

Review 8.  Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis.

Authors:  Thomas Hedner; Ola Samulesson; Peter Währborg; Hans Wadenvik; Kjell-Arne Ung; Anders Ekbom
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  Tight-binding inhibition by alpha-naphthoflavone of human cytochrome P450 1A2.

Authors:  Uhn Soo Cho; Eun Young Park; Mi Sook Dong; Bum Seok Park; Keehyuk Kim; Kyung Hyun Kim
Journal:  Biochim Biophys Acta       Date:  2003-05-30

10.  The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-A resolution.

Authors:  Michael R Wester; Jason K Yano; Guillaume A Schoch; Christine Yang; Keith J Griffin; C David Stout; Eric F Johnson
Journal:  J Biol Chem       Date:  2004-06-04       Impact factor: 5.157

View more
  6 in total

Review 1.  Formation and Cleavage of C-C Bonds by Enzymatic Oxidation-Reduction Reactions.

Authors:  F Peter Guengerich; Francis K Yoshimoto
Journal:  Chem Rev       Date:  2018-06-22       Impact factor: 60.622

2.  Diverging Mechanisms: Cytochrome-P450-Catalyzed Demethylation and γ-Lactone Formation in Bacterial Gibberellin Biosynthesis.

Authors:  Raimund Nagel; Reuben J Peters
Journal:  Angew Chem Int Ed Engl       Date:  2018-04-26       Impact factor: 15.336

3.  Isotope-Labeling Studies Support the Electrophilic Compound I Iron Active Species, FeO(3+), for the Carbon-Carbon Bond Cleavage Reaction of the Cholesterol Side-Chain Cleavage Enzyme, Cytochrome P450 11A1.

Authors:  Francis K Yoshimoto; I-Ji Jung; Sandeep Goyal; Eric Gonzalez; F Peter Guengerich
Journal:  J Am Chem Soc       Date:  2016-09-12       Impact factor: 15.419

4.  Presence or absence of microbiome modulates the response of mice organism to administered drug nabumetone.

Authors:  L Jourová; B Lišková; K Lněničková; N Zemanová; P Anzenbacher; P Hermanová; T Hudcovic; H Kozáková; E Anzenbacherová
Journal:  Physiol Res       Date:  2020-12-31       Impact factor: 1.881

5.  Practical Catalytic Cleavage of C(sp3 )-C(sp3 ) Bonds in Amines.

Authors:  Wu Li; Weiping Liu; David K Leonard; Jabor Rabeah; Kathrin Junge; Angelika Brückner; Matthias Beller
Journal:  Angew Chem Int Ed Engl       Date:  2019-07-01       Impact factor: 15.336

6.  Gel Formulation of Nabumetone and a Newly Synthesized Analog: Microemulsion as a Photoprotective Topical Delivery System.

Authors:  Fedora Grande; Gaetano Ragno; Rita Muzzalupo; Maria Antonietta Occhiuzzi; Elisabetta Mazzotta; Michele De Luca; Antonio Garofalo; Giuseppina Ioele
Journal:  Pharmaceutics       Date:  2020-05-05       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.